Big pharma stung in HHS fraud report

Half of the $4 billion in fraudulent health care claims recouped by the government last year came from big pharma. An HHS report cites fraud by drug and device makers, with Allergan's $600 million fine and settlement for off-label Botox marketing topping the list. Allergan is followed by Novartis Pharmaceuticals, with $422.5 million in fines; AstraZeneca, $520 million; Forest Laboratories and Forest Pharmaceuticals, $313 million; and Teva, $100 million. HHS release | Report (PDF)

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.